Fred Hutch: A Promising Antibody-Drug Conjugate for Treating Brain Metastases in Breast Cancer Patients

A recent study led by Dr. Sara Hurvitz highlights the promising results of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate that targets HER2-expressing cells to treat metastatic breast cancer. Approved by the FDA after phase II trials, T-DXd continues to show efficacy in patients whose disease has progressed despite prior therapies.